Did CareDx throw itself under the bus in terminating LabCorp lupus test deal?

CareDx, LabCorp Terminate Lupus Test Deal | GenomeWeb

As part of the agreement to terminate the collaboration, CareDx is transferring and assigning to LabCorp 300 “SAGE 1” clinical samples, as well as other clinical data and documentation that CareDx gathered from patients during the discovery phase of the collaboration.

CareDx also is granting LabCorp a perpetual, non-exclusive, worldwide, royalty-free license to use any IP and data resulting from the collaboration for any purpose. In return, LabCorp will pay CareDx $500,000. No other royalties, milestone fees, or other fees will be payable by LabCorp.

via CareDx, LabCorp Terminate Lupus Test Deal | GenomeWeb.

————————————-

All those law firms that are looking into LabCorp’s acquisition of Covance should consider how well the shareholders of CareDx made out in the making and breaking of this “deal.”